|
Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis. |
|
|
Consulting or Advisory Role - Amgen; Celgene (Inst); Roche; Takeda (Inst) |
Research Funding - Takeda (Inst) |
Travel, Accommodations, Expenses - Janssen |
|
|
Consulting or Advisory Role - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
Research Funding - Celgene; Roche |
Travel, Accommodations, Expenses - Celgene; Janssen |
|
|
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis; Pfizer; SERVIER |
|
|
Travel, Accommodations, Expenses - Alnylam; Pfizer |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Abbvie; Amgen; Celgene; Gilead Sciences; Janssen; Takeda |
|
|
Travel, Accommodations, Expenses - Amgen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Gilead Sciences; Novartis; Servier/Pfizer |
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen-Cilag; Roche; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Roche |
|
|
Research Funding - Novartis (Inst); Pfizer |
Travel, Accommodations, Expenses - Janssen; Pfizer |
|
|
No Relationships to Disclose |